NIH ACTIV-4B COVID-19 Outpatient Thrombosis Prevention Trial Ends Early

The data collected to date, through a randomized, double-blinded, placebo-controlled trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI), suggests a very low rate of thrombotic complications in the patients studied.
Source: BWH News - Category: Hospital Management Source Type: news